Background-Contrast medium-induced acute kidney injury is associated with substantial morbidity and mortality. The underlying mechanism has been attributed in part to ischemic kidney injury. The aim of this randomized, double-blind, sham-controlled trial was to assess the impact of remote ischemic preconditioning on contrast medium-induced acute kidney injury. Methods and Results-Patients with impaired renal function (serum creatinine Ͼ1.4 mg/dL or estimated glomerular filtration rate Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m
C ontrast medium-induced acute kidney injury (CI-AKI) is a serious complication of coronary angiography (CA). CI-AKI is one of the leading causes of hospital-acquired acute renal failure, accounting for 12% of all cases, and is associated with considerable morbidity and mortality. 1, 2 With increasing use of contrast medium in diagnostic and interventional procedures, the prevalence of CI-AKI is expected to rise in the next few decades.
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Preexisting renal dysfunction with estimated glomerular filtration rate (eGFR) Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 is the main predictor of CI-AKI, and its severity correlates directly with the incidence of CI-AKI. [3] [4] [5] Other risk factors for CI-AKI include diabetes mellitus, major cardiovascular comorbidities, hypovolemia, administration of high doses of contrast medium, and concomitant use of drugs that interfere with the regulation of renal perfusion. 5 Patients undergoing CA are generally at high risk of developing CI-AKI because of existing comorbidities. Unfortunately, resoundingly successful prevention options are lacking. Novel prevention and treatment strategies are required to decrease the incidence of CI-AKI and to preserve kidney function in patients undergoing CA.
In this respect, remote ischemic preconditioning (IPC) may offer a novel, nonpharmacological prevention strategy for decreasing CI-AKI incidence in patients undergoing CA. It is assumed that IPC confers protective effects on tissue or organ by multiple brief cycles of ischemia and reperfusion applied to another remote tissue or organ. This simple technique can be used in all medical centers worldwide.
The role of IPC in reducing the incidence of CI-AKI is unknown. In this prospective, randomized, sham-controlled pilot study, we hypothesized that IPC applied before CA may be beneficial in the prevention of CI-AKI in patients at high risk.
Methods

Study Population
Eligible patients were Ն18 years of age, presented with stable angina pectoris, and were admitted to the Cardiology Department of the University Hospital of Cologne for elective CA. The renal function test revealed impaired renal function with elevated serum creatinine of Ͼ1.4 mg/dL or reduced eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 6 No patient had end-stage renal failure with the need for hemodialysis.
This prospective, randomized, blinded, sham-controlled, singlecenter pilot trial was conducted from January 2011 until June 2011 at the University Hospital of Cologne, Germany. All patients gave their written informed consent.
Study Protocol
Sealed envelopes were used to randomly assign consecutive patients in a 1:1 ratio to receive 1 of the 2 treatments: Standard CA with sham preconditioning before CA (control group) or remote IPC before standard CA through intermittent upper-arm ischemia. In accordance with internal departmental guidelines, all patients received standard care for patients with impaired renal function undergoing CA: Oral N-acetylcysteine (NAC) 600 mg twice orally, the day before and on the day of CA, and continuous intravenous saline infusion (0.9%) 12 hours before to 12 hours after CA (1 mL per kilogram of body weight per hour); withdrawal of nephrotoxic drugs (eg, aminoglycosides, nonsteroidal anti-inflammatory drugs, calcineurin inhibitors, metformin, and others); and limitation of contrast medium application to
Ϫ1 . 7 The primary outcome was the incidence of CI-AKI, which was defined as an increment of serum creatinine Ն0.5 mg/dL or a relative increase of Ն25% over the baseline value within a period of 48 hours after contrast medium administration. Secondary outcomes were the maximum elevation of serum creatinine, cystatin C, and urinary neutrophil gelatinase-associated lipocalin (NGAL) in a 48-hour period after contrast medium exposure. The composite cardiovascular end point included death, rehospitalization, or hemodialysis during 6-week follow-up.
Procedures
IPC was accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff to the individual's systolic blood pressure plus 50 mm Hg to induce transient and repetitive arm ischemia and reperfusion. IPC was started immediately before CA. The time between the last inflation cycle and the start of CA was Ͻ45 minutes.
Sham preconditioning was performed in the same way as IPC, by inflating an upper-arm blood pressure cuff to diastolic pressure levels and then deflating the cuff for 10 mm Hg to maintain nonischemic upper-arm compression for blinding purposes with regard to the patients. To blind the physicians, investigators performing the preconditioning procedure (A.M.N., H.D., and K.M.D.) were not involved in any other data acquisition or statistical analysis.
CA was performed according to standard clinical practice. Percutaneous intervention was performed at the physician's discretion. In all patients, Accupaque 300 (iohexol; osmolarity 0.64 Osm/kg H 2 O at 37°C), a nonionic low-osmolar contrast medium, was used. The postprocedural period was divided into the acute phase during hospitalization (Ն48 hours) and follow-up (6 weeks after CA). Samples in the acute phase were obtained from all subjects during hospitalization. Data for the 6-week follow-up time point were acquired during patient visits in our outpatient clinic.
Study Oversight
The study protocol was approved by the local ethics committee and was designed in accordance with the Helsinki II declaration. The trial was conducted in accordance with the trial protocol. The Renal Protection I Trial (RenPro I Trial) was initially planned as a 2-step trial. The present first step was designed as proof of concept that IPC might be beneficial in patients at high risk for CI-AKI. On the basis of the results of the present study, a second extended trial (the RenPro II Trial) was designed to test the effects of IPC on cardiovascular mortality and morbidity. The advisory board recommended reporting the present preliminary results because of the observed clearly beneficial effects of IPC.
Statistical Analysis
We calculated the sample size on the basis of a power analysis that assumed a minimum clinically important difference of 10% difference between groups in the rate of the primary end point. We assumed a contrast medium-induced nephropathy incidence between 35% and 45% in the control group. 8 All variables were tested for normal distribution with the Kolmogorov-Smirnov test. Variables that conformed to normal distribution were summarized as means (SD) and otherwise as median and the first and third quartiles (Q1-Q3). We used Mann-Whitney U test and Fisher exact test to compare categorical variables. The effect of IPC on trial outcome was evaluated with univariable and multivariable logistic regression. The latter also included 2 of 5 prespecified risk factors (ie, age, diabetes mellitus, left ventricular ejection fraction, contrast medium volume, and volume of saline infusion) that showed the strongest "univariable" association with CI-AKI. A mixed model for repeated-measures analysis was performed to compare changes between groups of serum creatinine, urine NGAL, and cystatin C at different time points.
Statistical analyses were performed with SPSS 20.0. A 2-sided probability value of Ͻ0.05 was considered to indicate statistical significance; a Bonferroni correction was applied to probability values for 7 pairwise comparisons of groups at specific time points. Figure 1 shows the trial profile. A total of 267 patients were assessed for eligibility, but 153 did not fulfill the entry criteria of impaired renal function, 6 were undergoing a chronic hemodialysis program, and 8 did not agree to the protocol. A total of 100 patients (mean age 73.2Ϯ9.1 years; 71 men, 29 women) were included. Of these patients, 50 were randomly allocated to receive standard therapy (control group) and 50 to receive standard therapy plus IPC (IPC group). None of the patients were excluded after randomization. Table 1 shows demographic, angiographic, and clinical characteristics of the different treatment arms. The calculated risk score suggested an equal probability of developing CI-AKI in both groups. 8 On admission, the baseline serum creatinine concentration was Ͼ1.4 mg/dL (Ͼ124 mol/L) in IPC indicates ischemic preconditioning; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CI-AKI, contrast medium-induced acute kidney injury; and Q1-Q3, quartiles 1 and 3.
Results
*Normally distributed data are presented as meanϮSD and nonnormally distributed data as median (Q1-Q3); other data are shown as n (%).
†To convert the values for serum creatinine to micromoles per liter, multiply by 88.4. 86 patients (47 in the IPC group and 39 in the control group), and eGFR was Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 in all 100 patients. Patients with IPC received larger amounts of contrast medium because of a higher rate of percutaneous interventions in this group (control group 103Ϯ41 mL versus IPC group 124Ϯ44 mL). Cardiovascular medication use was similar in the 2 groups (Table 2) . Loop diuretics were withdrawn periprocedurally and started again the day after CA. In 40 subjects (40%), 19 (38%) in the control group and 21 (42%) in the IPC group, loop diuretics were given because of heart failure symptoms.
Overall, the primary study end point, contrast mediuminduced nephropathy, occurred in 26 patients: 6 (12%) in the IPC group and 20 (40%) in the control group (odds ratio in univariable analysis, 0.21; 95% confidence interval, 0.07-0.57; Pϭ0.002; Figure 2 ; Table 3 ). Multivariable analysis with adjustment for contrast medium amount and diabetes mellitus status revealed that IPC was a strong independent correlate for prevention of CI-AKI (odds ratio, 0.12; 95% confidence interval, 0.04 -0.40; Pϭ0.001).
Surrogate measures for acute kidney injury were acquired before and after contrast medium administration. Serum creatinine was similar in both groups at baseline (control group 1.62 mg/dL, Q1-Q3 1.39 -1.91 mg/dL; IPC group 1.63 mg/dL, Q1-Q3 1.47-1.81 mg/dL) and after 24 hours (control group 1.58 mg/dL, Q1-Q3 1.39 -2.00 mg/dL; IPC group 1.62 mg/dL, Q1-Q3 1.40 -1.85 mg/dL; Pϭ0.13) but increased significantly more after 48 hours in control patients (2.03 mg/dL, Q1-Q3 1.62-2.34 mg/dL) compared with patients with IPC (1.79 mg/dL, Q1-Q3 1.53-2.03 mg/dL; Pϭ0.003; Figure 3A ). Serum cystatin C increment 24 and 48 hours after CA also reflected major renal injury in the control group compared with patients with IPC (24 Figure 3C ).
Eighteen patients (9 in each group) underwent major cardiovascular surgery or intervention during 6 weeks of follow-up (10 coronary artery bypass surgeries, 6 surgical valve replacements, and 2 transcatheter aortic valve implantations). One patient underwent repeated CA. Data for these 19 patients were included until the date of surgical or interventional procedure and excluded thereafter. Outcome measures after surgical or percutaneous intervention are shown separately in Tables 4 and 5 . Seven patients required hemodialysis after surgery or percutaneous coronary intervention (7 in the control group versus 0 in the IPC group; 
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Pϭ0.001). Eight patients died after surgery or percutaneous coronary intervention (4 in each group).
The composite cardiovascular end point occurred in 27 patients, 19 (38%) in the control group and 8 (16%) in the IPC group (Pϭ0.018; Table 3 ). Two patients in the control group died during follow-up (1 of myocardial infarction and 1 of intracerebral bleeding; Pϭ0.49) versus no deaths in the IPC group. Rehospitalization was significantly less frequent in patients with IPC than in control patients (7 [14%] in the IPC group versus 18 [36%] in the control group; Pϭ0.016). The most common reason for hospitalization was dyspnea caused by worsening of heart failure symptoms (Table 6 ). Hemodialysis was necessary in 2 patients in the control group and in 1 with IPC (Pϭ1.00).
No major adverse events occurred during sham-control preconditioning and IPC. In 2 patients with IPC, 2 instead of 4 cycles of upper-arm ischemia were performed because of patient discomfort. Six additional patients with IPC developed mild reversible petechial spots distal to the blood pressure cuff.
Discussion
The present study demonstrates that remote IPC, induced by intermittent upper-arm ischemia before an invasive coronary procedure, dramatically reduces the incidence of contrast medium-induced nephropathy in patients with chronic kidney disease and high risk for CI-AKI. Additionally assessed surrogate measures support the preventive effect of IPC. This protective effect appeared to be independent of all other factors, eg, contrast medium amount and comorbidities of the patients. In addition, IPC significantly decreased the incidence of the composite cardiovascular end point, which consisted of death, hospitalization, or hemodialysis.
CI-AKI is a frequent and serious complication after CA with or without percutaneous coronary intervention. Moreover, CI-AKI has been shown to be an independent predictor of 1-year mortality in patients with coronary artery disease. 8 The incidence of CI-AKI varies substantially among several studies because of the lack of a uniform definition of CI-AKI. 9, 10 Rates of CI-AKI may be as high as Ͼ50%, depending on the presence of risk factors such as chronic renal insufficiency and diabetes mellitus or heart failure. 4, 8, 10, 11 In 2004, Mehran et al 8 developed a risk classification system to predict risk for contrast medium-induced nephropathy in patients undergoing CA. This most comprehensive and best-validated risk stratification score includes 8 clinical and procedural variables and is divided into 4 classes of risk of developing CI-AKI: Low (risk score Յ5), moderate (risk score 6 -10), high (risk score [11] [12] [13] [14] [15] , and very high (risk score Ն16). The calculated mean integer score for both groups in the present study was 13, thus determining the present study population as a group at high risk of developing CI-AKI (Ϸ60% of the subjects were at high or very high risk). Indeed, the reported incidence of 40% in the control arm of the study is within the reported range 12 and corresponds exactly to the serum creatinine-based CI-AKI incidence predicted by Mehran et al. 8 The demonstrated CI-AKI incidence in the present study cohort is higher than in other publications with comparable baseline eGFR. 13 This is attributed at least in part to the high incidence of comorbidities in the RenPro study population (Ϸ80% had congestive heart failure, and Ͼ60% had diabetes).
Despite its broader prevalence, the precise pathophysiological mechanisms of CI-AKI have not been elucidated clearly. The pathogenesis of CI-AKI is multifactorial, because vascular, hemodynamic, and tubular factors contribute to its development. The most common pathophysiological concept of CI-AKI is the induction of renal ischemic injury, possibly caused by iodinated contrast medium-induced reduction in renal blood flow and oxygen free radical-mediated direct tubular toxicity. 14 Other underlying mechanism for pathological changes in CI-AKI include contrast medium-induced natriuresis and diuresis, which activate the tubuloglomerular feedback response with subsequent vasoconstriction of the glomerular afferent arterioles, causing a decrease in glomerular filtration rate. To date, there is no effective prophylactic regimen to prevent CI-AKI. Dopamine, fenoldopam, furosemide, mannitol, aminophylline, atrial natriuretic peptide, captopril, calcium channel blockers, and alprostadil were not effective in reducing the incidence of CI-AKI. [15] [16] [17] [18] Initial studies assessing the ability of NAC to prevent CI-AKI were encouraging; however, the role of NAC in prevention of CI-AKI has been questioned, because subsequent larger trials failed to demonstrate an NAC-associated benefit. 19, 20 Likewise, there are inconsistent data on the effects of NAC on serum creatinine. In healthy volunteers with normal renal function and no exposure to contrast medium, there was a small but significant decrease in mean serum creatinine and urea concentrations and a significant increase in eGFR. 21 Levels of cystatin C remained unchanged after NAC administration. However, no change in serum creatinine or cystatin C was observed in patients with chronic kidney disease. 22, 23 Our hypothesis that IPC may be nephroprotective was largely based on earlier reports showing the beneficial action of IPC in several clinical settings. IPC has been reported to decrease the incidence of perioperative myocardial injury during cardiac surgery in adults 24, 25 and children 26 and to diminish both myocardial and renal injury incidence during surgery for endovascular 27 and open surgical 28 repair of abdominal aortic aneurysm. Very recently, IPC before hospital admission increased myocardial salvage by attenuation of reperfusion injury in patients with evolving myocardial infarction. 29 Although serum creatinine is the most widely used serum marker of renal function, serum cystatin C and urinary NGAL 
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have been reported to be more specific and sensitive to acute and early deteriorations in renal function. 30 -33 Indeed, serum creatinine is not an adequate marker for CI-AKI. 34, 35 Thus, Ͼ50% of renal function must be lost before an elevation in serum creatinine is detected. In addition, serum creatinine does not accurately depict kidney function until a steady state has been reached, which may require several days. 33 The serum cystatin C level and NGAL are more sensitive in identifying moderate renal insufficiency than the serum creatinine level. 36 Furthermore, cystatin C is not affected by renal tubular secretion or pharmacological treatments. 23, 37 In particular, NGAL has been shown to be an early, sensitive, specific, and predictive biomarker of acute kidney injury after contrast medium administration. 38 Therefore, both measures were also investigated in the present study and correlated well with the eGFR reduction and, subsequently, contrast mediuminduced renal damage. Consistently, both early markers of the CI-AKI were raised after exposure to contrast agent. This was evident at 6 and 24 hours after contrast medium application, whereas serum creatinine was unchanged at the same time.
Given the results of the present study, a novel concept of cytoprotection by IPC before CA may be considered for the prevention of CI-AKI in numerous patients. We calculated that 4 patients at elevated risk for CI-AKI have to be treated by IPC to prevent 1 CI-AKI (number needed to treat 3.6; 95% confidence interval, 2-9). Moreover, IPC can be applied easily, and virtually no safety concerns exist if it is performed appropriately. Even if the underlying mechanisms of IPCmediated beneficial effects remain largely unknown, the noninvasive IPC protocol is likely to have direct effects on decreasing renal ischemia/reperfusion injury incidence as part of the systemic protective effect of this phenomenon.
It has been postulated that a remote organ releases humoral factors such as adenosine or bradykinin into the systemic circulation, which subsequently protect the remote region or organ. Other underlying mechanisms may include erythropoietin, activation of the K ATP channel, nitric oxide, delta 1-opioid, and free radicals. 39 Some studies have also suggested that the protective effect of IPC may be caused by its beneficial anti-inflammatory or antioxidant effects and decreased extracellular levels of noxious metabolites, such as protons and lactate. 39, 40 Additionally, some other studies have favored a neurogenic pathway. 41 Overall, our concept suggests a humoral basis for the underlying renoprotective effects, because in the additional experimental setting, we found elevated erythropoietin plasma levels and mRNA expression in a reperfusion-ischemia mouse model (V. Burst et al, unpublished data, 2012). It is well known that reperfusion injury involves several pathways, including alterations in cellular metabolism, endothelial dysfunction, inflammation, hypercontracture, and necrosis/apoptosis. 42 Thus, IPC-mediated counterregulatory protective pathways may eventually offer an additional clinical benefit and contribute to better clinical outcomes.
Among those patients with major cardiac surgery or percutaneous coronary intervention, more control patients than patients with initial IPC required hemodialysis. Although this difference was statistically significant, the small number in the subgroup limits this effect, but it may merit further investigation.
However, the present study has several limitations. This pilot investigation of the beneficial effects of IPC on renal function is a single-center trial with a limited sample size. Although we sought to prevent any bias by blinding the patients and the data analysis team, the study design cannot prevent all influential effects. The a priori sample size calculation was based on inaccurate assumptions and calculations because of the pilot nature of the study. Nevertheless, it is of no question that the described hypothesis is a highly appealing and practicable method to reduce potential lifethreatening complications of organs in general.
In this study, we demonstrated that the simple and welltolerated application of IPC in high-risk patients with renal dysfunction undergoing CA reduced the incidence of procedurerelated CI-AKI. In addition, the nephroprotective effect of IPC was associated with improved clinical outcomes at 6 weeks. Thus, the use of IPC may be a feasible and highly attractive therapeutic procedure and should be investigated in future trials.
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